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Abstract 
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1. Introduction 
New Psychoactive Substances (NPS), also inaccurately known as ‘legal highs’, are those 
materials which lie in the grey area of legislative control in most countries and are used 
recreationally by psychonauts and at raves. According to the European Monitoring Centre for 
Drugs and Drug Addiction’s (EMCDDA) March 2015 report, the number of NPS is 
continuously increasing every year putting pressure on National Agencies to monitor these 
newly emerging drugs and to find solutions to reduce their harms [1]. The emergence of NPS 
has established itself as a global phenomenon appearing in some 94 countries worldwide as 
of December 2013 [2]. Furthermore, some NPS have much higher potency than the older 
drugs they are designed to replace while some are difficult to detect in body fluids [3]. NPS 
have rarely been studied for the purposes they are being used for and therefore pose a 
considerable and significant threat to the health of society. 
 
2. Methods 
The NPS names were entered as keywords into the search engines Google and PubMed. 
Around ten of the most relevant results on Google were considered and all relevant literature 
on PubMed was taken into account for each substance. Information was gathered from 
manufacturer’s websites, drug fora such as Bluelight, UK Chemical Research, Drugs-Forum, 
Reddit, TripSit and PsychonautWiki. 
 
3. Results and discussion 
3.1. Psychostimulants 
3-Fluorophenmetrazine (3-FPM;(1)), also known as PAL-539 (Fig. 1), has recently emerged 
in the online market of ‘research chemicals’ and is currently legal to possess and supply in 
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the UK as long as it is not for human consumption [4]. This compound is a relatively new 
substance and there are currently no scientific studies or literature pertaining to it. Psychonaut 
Wiki and drug fora such as Bluelight refer to the amphetamine-like its properties and3-FPM 
is a close relative to the now no longer used anorectic drug phenmetrazine (2), the chemical 
backbone of which can be likened to amphetamine with the terminal amine in a morpholine 
ring. According to Psychonaut Wiki, 3-FPM has not been used in humans prior to 2014, 
however, psychonaut communities who have experience with the drug have put up rough 
‘guidelines’ for its use. These suggest that a longest duration of action of 5-8 hours occurs 
when taken orally with a dose of 25-50 mg orally or 20-35 mg as insufflation for what is 
referred to as a ‘common’ effect [5].  
 
Fig. 1. The structures of commonly encountered psychostimulants 
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Physical effects described are increased energy levels, vasoconstriction, loss of 
thermoregulation, appetite suppression and an increased heart rate. Cognitive effects included 
increased motivation, focus and euphoria. Nonetheless, the stimulant effect was described as 
being less than that induced by substituted amphetamine compounds and users have referred 
to ‘flu-like’ symptoms with shivers [4,6]. Most of its effects could be inferred from the 
effects associated with phenmetrazine and other amphetamine-like drugs; therefore, part of 
this review will include some closely related compounds to which 3-FPM is related. 
Phenmetrazine is of the phenylmorpholine class of compounds and was developed as an 
appetite suppressant (anorectic) to be used in conjunction with a low caloric intake diet in the 
short-term treatment of exogenous obesity [7]. It was marketed under the trade name Preludin 
and was allegedly used by the Beatles early during their career to cope with long hours of 
performance. It is an indirect-acting sympathomimetic agent with central stimulant effects, 
and its mode of action and effects are similar to those of dextroamphetamine [7, 8]. Due to its 
high potential for abuse, considered to be more potent than amphetamine, it was withdrawn 
from the market [9]. It has been used recreationally and abused in Sweden in the 1950’s and 
in the USA in the 1960’s and 1970’s before being removed completely from the market [10]. 
The mechanism of action is highly similar to amphetamine by blocking the noradrenaline and 
dopamine re-uptake transporters in the brain which leads to their prolonged presence and 
hence prolonged stimulation of post-synaptic receptors at the synapse [11, 12]. 
Ritalin or methylphenidate (3) analogues such as 4-Me-TMP (4), made its appearance on the 
NPS market in April 2015 as a methylphenidate (3) replacement for the recently banned 
methylphenidate analogues EPH (5), PPH (6), IPH (7), 3,4-CTMP (8) and HDMP-28 (9) 
[13]. However, 4-Me TMP did not last long among psychonauts as it also was soon put under 
a Temporary Class Drug Order which took effect on the 27
th
 of June 2015 following 
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recommendations made by the UK Advisory Council on the Misuse of Drugs (ACMD), 
based on its similarity to methylphenidate in effects and inferred adverse effects [14,15]. 
Currently there are no scientific studies specific to 4Me-TMP as a recreational drug. A search 
on Pubmed using the keywords ‘4Me-TMP’, ‘4-Methylmethylphenidate’ returned no results 
as of 26
th
 of October 2015. Pharmacological data is limited with records of 4Me-TMP as one 
of the analogues of methylphenidate investigated in the treatment of cocaine dependence.  It 
was found to be slightly more potent than methylphenidate at inhibiting the binding of [
3
H]-
WIN35 428, a cocaine analogue used in research on the dopamine transporter [16, 17].  
In psychonaut communities, 4Me-TMP has gained popularity as a psychostimulant during its 
short span of ‘legality’. Users described it as the only ‘research chemical’ with effects closest 
to methylphenidate with a relatively lower potency that is concordant with available scientific 
pharmacological data [18]. Information regarding its effects in the human body can only be 
gleaned from reports of trips as posted or discussed on drug fora. Users reported euphoria, 
decreased appetite and need for sleep, increased alertness and focus and sexual arousal as 
positive and desired effects. Negative effects included increased sweating, tremors and 
tachycardia, however, the degree of the effects was subjective to the user.  Depending on the 
dose administered, 4Me-TMP was reported to be recreational resulting in a clear head and 
enabling users to improve performance during work or study.  Some users have recognised 
that as a methylphenidate analogue, 4Me-TMP may also have addictive potential, although so 
far, no compulsion to re-dose has been reported [19, 20].   
4Me-TMP has been mainly taken orally or by insufflation and oral doses vary from a 
recommended threshold of 25 mg to 90-125 mg as a heavy dose, with an onset of action 
within minutes and a duration of action of 4-6 hours. For insufflation, doses are smaller with 
a threshold of 10mg and a heavy dose of over 70 mg with an onset of action within minutes 
and a duration of action of 2-5 hours.  Doses are sometimes ‘boosted’ after 3 hours of 
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administration for a prolonged effect [18, 19, 21, 22].  Varying degrees of harm from drug-
drug interactions when using methylphenidate are also warned of on the Tripsit website. For 
instance, concomitant use of stimulants and tramadol are said to increase the risks of seizures 
and are qualified as dangerous. Increased risk of serotonin syndrome is noted with 
simultaneous use with monoamine oxidase inhibitors and 2C-T-x compounds (e.g. 10).  
Excessive anxiety with persistent thought-loop is also purported to occur when 4Me-TMP is 
used with psychedelics such as mescaline. 4Me-TMP as a psychostimulant is also said to 
decrease the perception of drunkenness and increase the risk of drinking excessively till the 
passing out point [21]. 
The fora threads on 4Me-TMP are relatively short possibly because of its short span of use as 
an NPS.  Nevertheless, users have so far reported few negative effects and are positive about 
4Me-TMP with people still seeking it out.  New posts appear to come from users who are 
apparently based outside the UK for example in Sydney [18], which suggests that 4Me-TMP 
has spread globally. For the time being, there is still no scientific evidence specific to 4Me-
TMP (26
th
 October 2015) apart from its inferred effects from structural similarity to 
methylphenidate, to validate its permanent ban under UK law. 
Methiopropamine (11) as an NPS was first reported following a seizure in Finland in January 
2011[23]. Its synthesis however, dates back to the 1940s when it was synthesised by Blicke 
and Burckhalter as an analogue of methamphetamine, where the phenyl ring was substituted 
with a thiophene ring in order to compare effects on blood pressure [24].  
Since its appearance online as a research chemical in late 2010, methiopropamine has become 
an established NPS used recreationally and evading control under the UK legislation until a 
temporary class drug order at the end of 2015. According to an internet snapshot study 
conducted in June 2013 in accordance with EMCDDA methodology, it was found that 
methiopropamine is readily available over the internet with 45% of vendors identified as 
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being UK-based.  It is sold mainly in powder form in amounts ranging from 150 mg to 4 kg 
[25]. This NPS was also detected in pooled urine collected from urinals placed in Central 
London on Friday and Saturday nights in 2012 as part of a pilot study to understand 
prevalence of NPS use [26]. It was also detected in the blood samples from drivers in Norway 
[27]. 
An analysis of the metabolites of methiopropamine from rat and human urine by GC-MS and 
LC-HR-MS was conducted by Welter et al 2013.  This proposed that methiopropamine 
underwent a combination of N-methylation and hydroxylation at the side-chain and thiophene 
ring respectively before glucuronidation and sulfation.  The CYP450 enzymes involved were 
CYP1A2, CYP2C19, CYP2D6 and CYP3A4 [28]. 
It seems that users have been utilizing methiopropamine as a performance enhancer to cope 
with work, study and bereavement as well as recreationally [31, 32, 38]. Methiopropamine is 
being ingested orally, smoked, used as an insufflation, taken rectally or injected intravenously 
by psychonauts depending on the effects desired.  For instance, small doses of 10 mg taken 3 
hourly by IV injection to maintain a high or a bolus of 40-50 mg for a ‘rush’ have been 
suggested [32].  The threshold dose is noted as 10 mg with a 60 mg+ dose as being heavy.  
Onset of action is within 30-60 minutes with the effects peaking at 2-4 hours, with a coming 
down that lasts 2-3 hours and an afterglow experienced for 1-3 hours [33]. Insufflation is 
reported to leave a bad taste which may be due to the sulfur atom in the molecule but 
provides the same intense rush as IV injection with a shorter duration of action [32].  An 
analysis of the pyrolysis products of methiopropamine under the same conditions when 
smoked by users found that they were mostly the same as methamphetamine. However, other 
products were also formed such as beta-keto-methiopropamine, whose properties are 
unknown, N-methyl methiopropamine which is psychoactive, 2-methylthiophene which is 
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toxic and a bicyclic tetrahydropyridine compound with a structure similar to the anti-platelet 
drug clopidogrel [29]. 
As an analogue of methamphetamine, methiopropamine has also been reported to induce 
similar effects.  This was supported by a study of neurochemical profiling of NPS by Iversen 
et al (2013) in which methiopropamine was found to be a potent inhibitor of noradrenalin, 
dopamine and to a lesser extent serotonin re-uptake comparable to amphetamine [30]. Users 
report an increased alertness, energy and focus, sexual arousal and euphoria on drug fora 
which is described as a ‘rush of adrenaline’. Side-effects also noted were high-blood 
pressure, tachycardia, anxiety, sweating and shaking, nausea, dehydration, difficulty urinating 
and a significant loss of appetite and sleep which could last for days. Quite a few users also 
reported chest pain, palpitations and headaches sometimes comparable to a heart-attack. 
Users recommended taking multivitamins, drinking plenty of water and Gingko biloba for its 
vasodilating effects to minimise the harmful effects of methiopropamine. Negative effects 
were said to increase with repeated dosing and to cause hallucinations at high dose. Chronic 
use multiple times a day and/or over several consecutive days was reported to cause 
psychosis, hallucinations and heightened fear and anxiety, depression and aggressive 
behaviour on withdrawal [31–39]. Methiopropamine was also regarded as highly addictive 
with a strong compulsion to re-dose and binge accompanied by a loss of inhibition at high 
doses. This addictive character was suggested to be in part a psychological need to feel the 
‘intense euphoric rush’ by users [35, 32]. Tolerance was also said to build up very quickly 
with loss of positive or desired effects [38, 39]. In drug fora, prospective users are warned not 
to binge on methiopropamine and an awareness of its potentially-life threatening side-effects 
seems to be prevalent [31-39]. 
Methiopropamine use has already claimed lives as it continues to gain followers despite some 
discouraging user reviews online [32, 39].  In 2012, two methiopropamine-related deaths 
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were first reported in the UK [23] while the first ever case in Australia was reported in 2015 
where a post-mortem investigation found 38mg/L of methiopropamine in the blood of the 
deceased [40]. Acute toxicity related to methiopropamine where 400ng/ml was found in 
urine, has also been reported.  In that particular case, however, the user bought their samples 
from a Central London market stall under the name of ‘Quicksilver’. Considering that the 
only reference to ‘Quicksilver’ in a recreational drug context that could be found online was 
of methoxetamine, it is possible that the victim may not have been aware of what they were 
ingesting [41].   
Methiopropamine is appealing to many users as a euphoric psychostimulant that can be 
employed in multiple situations in spite of its notorious side-effects. Use will probably 
continue to spread worldwide via its boundary-less cyber foothold unless any action is taken 
whether in terms of legislative control or harm reduction and drug use education measures. 
 
 
3.2.Lefetamine-derived dissociative anaesthetics 
Following the UK ban in February 2013 on all arylcyclohexylamines in an attempt to curtail 
the spread of PCP and ketamine analogues, a new class of dissociative anaesthetics known as 
diarylethylamines based on lefetamine (12) among which can be found ephenidine (13), 
diphenidine (14) and methoxyphenidine (15), hit the NPS market as crystals, powder and 
pellets to circumvent the law [42] (Fig. 2).   
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Fig. 2. Lefetamine-derived dissociative anaesthetics 
Diarylethylamines, which are far from being novel, have actually been synthesised and 
documented as far back as 1924 [43]. Diarylethylamines are in fact, analogues of the now 
withdrawn and controlled drug lefetamine (12), which was introduced as an opioid analgesic 
in the 1940s and marketed as Santenol [44]. 
However, despite their structural resemblance to lefetamine, these diarylethylamines do not 
have the same pharmacological activity, mimicking instead the effects of PCP and ketamine, 
and their respective analogues function by uncompetitive NMDA-receptor antagonism and 
are being marketed as their legal replacement by online chemical vendors [43, 45]. Indeed, 
from a thread on Bluelight, it seems that lefetamine and lefetamine-derivatives have been 
compared to the arylcyclohexylamines PCP and ketamine and their use as possible 
recreational drugs was discussed as early as 2006 [46].  
While these compounds have been gaining in popularity across the psychonaut communities, 
again little is known about them. Most of the information reported about their physiological 
effects in humans comes from online drug fora and some from cases of NPS poisoning sent to 
emergency services.  So far, Sweden has already classified them as hazardous to human 
health [47] and this review seeks to bring an overview of the information available so far. 
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Ephenidine (13), first appeared on the NPS scene in 2008 when it was seized alongside 
NPDPA (16), another lefetamine derivative, by the German police. Nonetheless its 
amphetamine-like stimulant properties had already been described in the 1940s [48]. From 
the metabolites collected from rat urine, it was inferred that ephenidine was completely 
metabolised and most likely underwent a combination of N-alkylation, mono- and bis-
hydroxylation of the benzyl ring followed by methylation of one of the two hydroxyl group 
metabolites at phase 1, and hydroxylation of the phenyl ring after N-dealkylation, 
glucuronidation and sulfation of all hydroxylated metabolites in phase 2 [48] Since the 
metabolism of ephenidine has been found to involve at least four CYP-450 enzymes to 
varying degrees, it has been purported that ephenidine may not give rise to significant drug-
drug or drug-food interactions [44]. 
In the Psychonaut communities, a thread was first dedicated to ephenidine and other related 
dissociative NPS in late December 2014 on Bluelight.  However, it seems that ephenidine is 
only recently starting to gain wider acceptance and popularity according to the drug fora 
studied [49, 50].  Often, reference is made to its smooth or ‘silk-like’ come-up compared to 
other dissociative anaesthetics [52] but also of a tendency to feel dehydrated.  The experience 
is also viewed as much more positive with a greater cornucopia of visual stimulation and 
hallucinations and also as less ‘out-of-body’ at regular doses. In some cases, users reported its 
effects as more ‘spiritual’ or ‘magical’ with an enhanced appreciation for music and colours 
[51, 52, 50]. One user even stated that ephenidine surpasses ketamine, PCP and all other 
dissociatives [53]. Ephenidine has also been reported to have mild psychedelic effects while 
scarcely affecting ‘functioning as a person’ [56].  Furthermore, it was also seen as an 
alternative to ketamine and methoxetamine by another user [57].   
Psychonauts have been administering the drug orally, rectally, by sniffing or vaping and by 
the IV route.  Doses employed are sometimes seen to be quite high, ranging from 150mg to 
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600 mg in some cases to achieve desired effects, though websites such as Psychonaut Wiki 
indicates a threshold of 60mg with a 200 mg+ dose being seen as ‘heavy’ [50, 54]. This 
suggests that ephenidine might be less potent or that the negative effects are more tolerable. 
Ephenidine is also reported to have a slow onset depending on individuals ranging from 10-
30 minutes to 1.5-3 hours but also a longer duration of action of 5-7 hours [50, 54, 55].  Full 
recovery from the dissociative effects also seem to vary among individuals with some still 
feeling wobbly after 15 hours after a 250 mg dose while others took a full 24 hours to recover 
after a 200 mg dose [55]. This may of course be as a result of the quality of the product as 
well as individual pharmacogenomic responses. 
Overall, most ‘user reviews’ appear in favour of ephenidine with apparently no distressing 
mental stimulation and a more enjoyable trip with seemingly no negative effects except for 
residual dissociative effects post use. Nonetheless, ephenidine is regarded as having a 
potential for addiction and prospective users are warned to use it carefully [57].   
On the side, two other variants of ephenidine that so far seem to be less popular among 
psychonaut communities are 2-chloro-ephenidine(26) and 2-MeO-ephenidine(27) [49]. 
Diphenidine (14) was first synthesised in 1924 by Christiaen who used a modified Brulyants 
reaction which would later be used by Maddox to synthesise PCP [43].  Though it was 
launched earlier than methoxyphenidine, it is less popular [58]. 
As a diarylethylamine, diphenidine has been investigated for neuroprotective effects on 
neurones in the hippocampus as described in a 1989 patent and furthermore its ability to 
suppress cough as an antitussive agent in dogs has also been studied. These past observed 
properties are what might have made it a candidate as a research chemical [59]. The NMDA-
receptor antagonist effect has recently been confirmed in-vivo using rat hippocampal slices 
and was found to be similar to ketamine in reducing NMDA-mediated field excitatory post-
synaptic potentials at 30 M [59]. Though not of the same chemical class, diphenidine 
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definitely does act as a pharmacological analogue to the dissociative drug ketamine.  
Dopamine and serotonin re-uptake inhibition and mu-opioid receptor affinity are purported 
by vendors but have however, not been studied [60]. 
According to Tripsit, a normal dose of diphenidine would be approximately85-110mg, with 
an onset of action of 10-30 minutes, a duration of 2-5 hours and an ‘after-glow’ effect of up 
to 4-24hours [61]. The most common route of administration is oral or sublingual. Blocked 
nose or inflamed sinuses have been reported with insufflation, although it is believed to have 
a quicker onset of action by this route requiring a fifth of the oral dose [63, 61]. 
Diphenidine is described as mildly stimulating and mostly amnesia-inducing, crippling the 
recall ability of the user which may potentially cause loss of control over one’s own 
behaviour [62]. An example is that of a previous ketamine user who overdosed on 
diphenidine orally at 310mg, was violent with the paramedics who came to take him to 
hospital and could not remember any of what had happened [63]. Other effects noted are 
those of sensory dissociation, loss of inhibition, and significant visual and internal 
hallucinations. Several users also reported high blood pressure and tachycardia. This was 
reflected in non-fatal intoxication cases of diphenidine observed in Sweden [61, 45].  
Diphenidine has not been very popular with many users reporting negative and sometimes 
both physiologically and psychologically troubling experience described by one user as being 
‘sucked down into a shrieking vortex of insanity’ [58]. Of most concern is the steep dose 
response curve reported with a rapid build-up of tolerance at higher doses and high addiction 
potential, which is described as very compulsive [63, 45, 64].  Diphenidine has even been 
described as ‘evil’ by another user [64]. 
Methoxyphenidine (15), is also member of the diarylethylamine group that has been screened 
for the potential treatment of neurotoxic injury according to a 1989 patent [66]. 
Methoxyphenidine appeared shortly after diphenidine and gained a rapid rise in popularity 
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relative to the latter despite an initial dearth of reports of previous human use of the 
compound [58].  Methoxyphenidine has been and is still being used extensively by the 
psychonaut communities.  
However, while it is being marketed by online vendors as a replacement for methoxetamine 
and ketamine, the effects of methoxyphenidine are reported to be qualitatively closer to those 
of dextromethorphan, an antitussive which has been abused. Subjective physical effects 
which include tactile disconnection, a spontaneous tactile sensation described as ‘body high’ 
and loss of motor control are reported to increase with increasing dosage and are reported to 
feel like those induced by dextromethorphan [67].   
Furthermore, the cognitive effects are seen as different from all other dissociatives with the 
user still being in control and less confused even at higher dosages to bring about the same 
subjective intensity when using methoxetamine, dextromethorphan or ketamine [58, 67]. A 
methoxyphenidine experience has been qualified as ‘introspective’ by one user-blogger [70].  
An in-depth review of harm reduction and online consumerism of methoxyphenidine among 
psychonauts conducted by Van Hout and Hearne supported that its effects are perceived as 
unique and result in a more ‘clear-headed’ sensation. It was also viewed as much better than 
diphenidine in that it is less ‘havoc-provoking’ with more enjoyable effects [58].  
Routes of administration are oral, sublingual, rectal, insufflation and by IV [58].  
Insufflations are said to irritate the nasal mucosa significantly [68, 70] and a numbness of the 
tongue is said to occur with IV administration and is therefore not the most favoured route 
[58].  Psychoactive effects are said to start at a dose ranging from 30 to 50 mg with 150+ mg 
being regarded as giving strong effects. The onset starts from 30 to 60 minutes with a 
duration of action of between 6-8 hours and after-effects are described as ‘after-glow’ of 1-3 
hours [67, 69].  Sometimes, even at higher doses of 200 mg, some users reported being 
reasonably lucid [56]. Whilst a steep-dose response curve has been reported, it is also said 
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that re-dosing is unnecessary as there is not much enhancement of positive effects but instead 
a higher risk of experiencing negative side-effects such as amnesia [43, 68].  Nevertheless, 
the dose-response effect of methoxyphenidine is reported as inconsistent and unpredictable 
with different users experiencing a differing degree of intoxication/side-effects at the same 
dosage [68].  Novice users as well as users who are experienced with dissociatives are often 
advised to start at the lowest dose as even with past dissociative usage, the effects of 
methoxyphenidine have been reportedly experienced as strong [70, 71]. 
On drug fora, users are reminded not to ‘push too far’ with this compound as it has been 
reported to cause chest pains, palpitations, tachycardia, high blood pressure and sometimes 
seizures requiring hospitalization [43, 56, 58, 70]. Indeed, during a relatively short span of 
use, cases of methoxyphenidine-related deaths and acute toxicity have already been reported 
[45, 65, 66].  An acute toxicity case of a 53 year old Caucasian male presented with 
hypertension at 220/125 mmHg and tachycardia of 112 bpm was treated with lorazepam, 
whilst an enlarged heart was found at the autopsy of two of the fatal cases attributed to 
methoxyphenidine [65, 66].  The acute toxicity case also developed opisthotonus and 
horizontal nystagmus upon losing consciousness before reaching a Glasgow Coma Scale of 
10 [65]. 
Despite the grave side-effects of methoxyphenidine that are possible, its positive effects of 
mood-elevation and as a brain stimulant with ‘responsible’ use were seen as important 
enough to lead psychonauts to speculate about its medicinal potential as an antidepressant 
and in psychotherapy [58].   
Possible further lefetamine-based dissociative anaesthetics may find their roots in previously 
studied analogues of lefetamine as suggested by one Bluelight thread dating back to 2008 
which briefly discusses DMPP (19), a compound investigated for analgesic properties [72].  
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On the whole, the psychoactive agents, ephenidine, diphenidine and methoxyphenidine are an 
emerging class of dissociative anaesthetics that have not been explored in that sense before. 
Their effects are being widely reported by psychonaut communities, definitely warrants 
further investigation and it is reasonable to expect new lefetamine analogues on the NPS 
market in the future. 
 
3.3.Phenylalkylamine hallucinogens 
Alexander Shulgin was the first to synthesise the phenylalkylamine hallucinogens 2C-B (20) 
(Fig. 3), DOB and DOM and described their syntheses and effects in PiHKAL [73].  While 
DOM and DOB were already established, 2C-B really flourished in the recreational drug use 
sphere in the mid-1980s as the best alternative to LSD and psilocybin [74, 75].  However, the 
2C-B class were soon banned in the US in 1985 and placed in Schedule 2, as Class B drugs in 
the UK. However, 2C-B still found its way into raves being often disguised as MDMA. 
 
Fig. 3. Commonly encountered phenylalkylamine hallucinogens in this study 
In recent years, as an attempt to find a legal substitute to 2C-B, vendors have come up with 
bk-2C-B (21) also known as beta-keto 2C-B, which hit the shelves of online head-shops in 
mid-2013 being sold as powder or crystals.  Because of its structure, bk-2C-B is not regulated 
to date in the UK or Ireland though it can be considered as the beta-keto analogue or a 
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cathinone analogue of 2C-B [76].  bk-2C-B appeared online in 2007 in a Bluelight forum 
thread discussing its potential as a future ‘legal-high’ replacement for 2C-B focusing on its 
possible dimerization (22) which could lead to inactivity of the compound in-vivo[77].  An 
even earlier appearance can be traced back to 2004 in a paper published by Glennon et al as 
an intermediate in the synthesis of beta-oxygenated analogues of a 5-HT2A serotonin receptor 
agonist investigated in the treatment of intraocular pressure [78].   
Analogous to 2C-B, bk-2C-B is deemed to be active at serotonergic receptors although 
scientific pharmacological data are limited.  It was gathered from anecdotal evidence posted 
on drug fora that bk-2C-B provides a psychedelic experience comparable to 2C-B [77], 
curiously though no article on bk-2C-B is yet available on Psychonaut Wiki. From other 
sources, users describe typical psychedelic effects of visual hallucinations, sensory 
enhancement and sometimes a greater appreciation of food and music is mentioned with 
euphoria and empathogenic experiences. [77, 79, 80]. Predominantly bk-2C-B is viewed as 
having scarce negative effects and seems to be appreciated though it is not always a favourite 
regarded by a few as ‘bland’ or ‘empty’ with little excitement and some users said they still 
prefer 2C-B. The quality of the trip is said to be dependent on the state of mind prior to taking 
the drug [77, 82, 81].  
It is also said to be 10 times less potent than 2C-B, initially requiring higher doses for the 
same effect but past a 150 mg dose, a steep dose-response curve is reached which warrants 
careful proceeding. The drug has a threshold of 50-60 mg and a 150 mg+ dose is seen as 
heavy while many users report that a proper ‘trip’ is achieved at 100 mg.  The drug has been 
taken orally, rectally and insufflated with encapsulation of an oral dose preferred over 
dissolution in water to avoid the aforementioned dimerization. Reports indicate that it has an 
onset of action of 20-70 minutes and a duration of 8-12 hours [77, 79, 82]. However, the 
effects of bk-2C-B have also been reported as inconsistent, one report even describing it as 
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‘Russian Roulette’ as the onset and duration of action were not always predictable at a given 
dose [83] 
Despite being apparently relatively ‘safe’, there has been a report of a 25 year-old male user 
with no previous history of heart disease who experienced a cardiac arrest following a dose of 
140 mg of bk-2C-B.The person suffered amnesia lasting two days after re-gaining 
consciousness and suffering from severe rhabdomyolysis [84].  Indeed, from several posts, 
psychonauts state that they are not willing or that it is not necessary to try a dose above 100-
120 mg as they deemed that the desired effects do not increase significantly and that it might 
be more dangerous to do so [77,82]. 
It is to be noted that despite being on the market since mid-2013 and showing similarity of 
action to 2C-B from drug forum posts, bk-2C-B has not conquered the recreational field of 
psychonauts in spite of being qualified as a ‘good chemical’.  
3.4 Psychdelics: LSZ and 1P-LSD 
NPS analogues of the classic psychedelic LSD (23) include two potent analogues LSZ (24) 
and 1P-LSD (25) (Fig. 4).  Very little scientific data exists regarding their pharmacological 
properties while they have been widely adopted by the psychonaut community ever since 
their appearance on the NPS market. 
 
 
Fig. 4. The structures of LSZ and 1P-LSD 
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LSZ is currently classified as a Class A Schedule 1 Drug in the UK since 6
th
 January 2015 on 
recommendation of the ACMD based on the fact that LSZ is an analogue of the controlled 
drug LSD and as a tryptamine-based drug it will have similar effects [85].  LSZ was 
synthesised and documented back in the early 2000’s by Nichols et al (2002) as a 
conformationally constrained analogue of LSD. It was found that the S, S isomer of LSZ was 
slightly more potent than LSD itself and showed greater binding affinity to 5-HTA receptors 
in rats, therefore being responsible for its hallucinogenic properties [86]. It appeared on the 
NPS highs market 7 years later in 2009 [87]. 
1P-LSD however, is only a recent addition to the lysergamide family, appearing in January 
2015 and has apparently been designed to provide an alternative to LSZ as it was banned. 1P-
LSD is also believed to be slightly more potent than its parent drug LSD [88]. This was 
demonstrated in a study in mice by Brandt et al where it was found to display approximately 
38% more potency than LSD [89].   
Both LSZ and 1P-LSD have been marketed in the form of blotters containing usually 150 
micrograms of the substance which is placed under the tongue in a similar fashion to LSD.  
1P-LSD is also available in tablet or ampoule forms [98].  Threshold dosage for LSZ is said 
to be 80 micrograms and between 150-300 micrograms to achieve a common effect.  The 
onset of action is 90-120 minutes with a duration of action lasting from 7 to 10 hours.  After-
effects can be felt for up to 1 to 3 hours [90].  On the other hand, 1P-LSD seems to be more 
potent with a threshold dose of 50 micrograms and 150+ micrograms as a heavy dosing.  The 
onset of action is also faster, starting at around half the time and a much longer duration of 
action lasting up to 12 hours with after-effects lasting up to 24 hours [88]. 
Users report mostly similar effects to those of LSD with experiences such internal-external 
visual hallucinations, loss of ego, empathy, euphoria, increased tactile sensation and 
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perception alteration.  Tripping experiences are subjective and varied with the occurrence of a 
positive experience more likely with a ‘positive mindset’ and a negative experience more 
likely with the opposite or with exposure to an object of fear and/or disdain during tripping.  
Users also sometimes reported ‘self-realisation’ or ‘spiritual’ experiences whilst tripping.  
The effects have been reported to significantly alter cognitive functions enough to endanger 
the user if in a potentially unsafe situation in that state such as walking on roads.  Physical 
manifestations are sweating, chills, pupil dilation, nausea and decreased appetite. Overall, 
however, most trip reports of LSZ or 1P-LSD are positive with users often reporting a more 
positive outlook on life afterwards and an agreeable experience they are willing to repeat.  So 
far, no acute toxicity cases or hospitalisation were reported with either LSZ or 1P-LSD.  Both 
LSZ and 1P-LSD are deemed to have no addictive potential and very low toxicity by users 
[88, 90-101].  One user, however, did report excessive nausea after taking a significant dose 
of 600 micrograms of LSZ but acknowledged to having overdosed [95].  
It seems that to date, lysergamides remain popular amongst psychonauts with uses ranging 
from recreational to introspective to spiritual.  Furthermore, their ‘apparent safety’ and low 
addiction and recoverable tolerance make them a drug of choice of this community.  
3.5 Benzodiazepines: flubromazepam 
Benzodiazepines are used in the psychonaut community to temper the effects of stimulants 
and hallucinogenic drugs to ‘come down’ while some people may use them as self-
medication for anxiety disorders when they cannot get a prescription.  Benzodiazepines are 
also used in the clinical setting to treat cases of acute toxicity related to NPS use [102].  
However, benzodiazepines are also used recreationally and the scheduling of the etizolam 
and phenazepam in 2012 led to the advent of new designer benzodiazepines made available 
to the public through online vendors.  Flubromazepam (26) is the second of the class to be put 
on the market and was a drug candidate described first in 1962 by Sternbach et al.  Its 
21 
 
potency is said to be possibly higher than those of bromazepam, diazepam and nitrazepam 
[102,103].   
Research into the pharmacokinetics and pharmacodynamics of flubromazepam is pretty 
scarce with only one study found on Pubmed at the time this review where one of the authors 
actually ingested 4mg of the drug to obtain data [103].  Flubromazepam has been reported as 
having a half-life of more than 106 hours with metabolites detectable by LC-MS/MS for up 
to 28 days after consumption.  However, detection of the drug with immunochemical assays 
were difficult and may indicate that its detection in  drug-facilitated crimes may not be 
conclusive [103]. 
The effects reported in psychonaut drug fora are typical of benzodiazepines such as muscle 
relaxant, anxiolytic, hypnotic and sedation and amnesia noted at higher doses.  For some 
users, flubromazepam is regarded as more anxiolytic than hypnotic and for others the reverse 
was true.  The routes of administration employed seem to be mainly oral, sublingual and 
rectal as the drug comes mainly as pellets of 4 mg or 8 mg. Flubromazepam indeed seems to 
be quite potent with a threshold dose of 3-5 mg and a heavy dose of 16+ mg.  However, the 
onset of action is not immediate, taking between 30 minutes and even up to 6 hours before 
any effect is noted.  This has led many to overdose on their first attempt with unpleasant 
consequences.  The effects are also reported to last for up to a few days.  Users seem to 
recognise that this long duration of action can have potential impact on safety when driving 
or operating machinery.  The danger of cumulative toxicity with reported dosage is also 
mentioned as is its addictive potential [104-108].  One user even reported withdrawal 
symptoms as soon as after one week’s use [109]. Concomitant use with other depressants 
such as alcohol or GBH is warned against to avoid potential respiratory depression [104]. 
Nonetheless, flubromazepam is regarded as one of the ‘best’ NPS benzodiazepines with the 
effects viewed as pleasant with a few cases of appreciated mild psychedelic effects reported.  
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Due to its apparent greater perceived effects than diazepam, some users have discussed its 
use in treating alcohol withdrawal instead of the latter [106]. Furthermore, awareness of the 
difficulty to detect in immunochemical assays is already causing some benzodiazepine users 
to consider it to escape drug-testing [110].  
Whether or not flubromazepam’s potential as a useful drug candidate can be revived is yet to 
be determined with the lack of research on this substance. Meanwhile flubromazepam 
continues to remain in the confines of the grey area of legislative control along with other and 
emerging designer benzodiazepines without any reliability of safety of use.   
4. Conclusion 
From this review, the dire lack of pharmacological data available on these substances was 
obvious as was their popularity of use among psychonauts.  A trend observed in most of the 
compounds selected was their origin from old patents and papers on drug candidates which 
have not been developed further and which can be found online.  Not only was the wealth of 
scientific information exploited by research chemical vendors themselves, but also actively 
discussed by psychonauts on drug fora even before the appearance of these NPS on the legal 
high market as is the case of bk-2C-B or lefetamine-based drugs.  As such, it makes sense to 
consider the content on drug fora as well as previous or abandoned drug candidates to try and 
spot upcoming NPS.  Furthermore, it should be noted that trip reporting on drug fora provides 
a wealth of information on the effects of NPS on the human body albeit by subjective views, 
and may also be a trend-setter in the development of future NPS.  Another interesting issue 
was that NPS were discussed not only as recreational drugs but for their therapeutic value in 
treating conditions such as depression and anxiety, for instance, in the case of ephenidine.  Of 
concern, is the very strong addiction potential of some drugs reviewed such as diphenidine or 
the potentially hazardous and easily overdosed psychostimulants and psychedelics and the 
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ease of access to them. It should be noted that acute toxicity cases requiring hospitalization 
and even deaths ensuing from NPS use have also been well reported.    
In any case, NPS which represent a largely unknown and rapidly expanding territory in an era 
of globalization and instantaneous access to information through the World Wide Web, will 
not be easy to conquer nor overlook. It may not be completely surprising if the next 
generation of antidepressants, psychotherapy counselling aid or the next schizophrenia-
modelling drugs were to come from NPS nor would it be surprising if the next addictive or 
crime-facilitating drug were to come from the NPS as well. 
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Abstract 
The purpose of this review is to identify emerging or new psychoactive substances (NPS) by 
undertaking an online survey of the UK NPS market and to gather any data from online drug 
fora and published literature. Drugs from four main classes of NPS were identified: 
psychostimulants, dissociative anaesthetics, hallucinogens (phenylalkylamine-based and 
lysergamide-based materials) and finally benzodiazepines. For inEach of the classes 
contained drugs that are modelled on existing illegal materials and will be covered by the UK 
New Psychoactive Substances Bill in 2016. 
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New Psychoactive Substances (NPS), also inaccurately known as ‘legal highs’ are those 
materials which lie in the grey area of legislative control in most countries and are used 
recreationally by psychonauts and at raves. According to the European Monitoring Centre for 
Drugs and Drug Addiction’s (EMCDDA) March 2015 report, the number of NPS is 
continuously increasing every year putting pressure on National Agencies to monitor these 
newly emerging drugs and to find solutions to reduce their harms [1]. The emergence of NPS 
has established itself as a global phenomenon appearing in some 94 countries worldwide as 
of December 2013 [2]. Furthermore, some NPS have much higher potency than the older 
drugs they are designed to replace while some are difficult to detect in body fluids [3]. NPS 
have rarelybeen studied for the purposes they are being used for and therefore pose a 
considerable and significant threat to the health of society. 
 
2. Methods 
The NPS names were entered as keywords into the search engines Google and PubMed. 
Around ten of the most relevant results on Google were considered and all relevant literature 
on PubMed was taken into account for each substance. Information was gathered from 
manufacturer’s websites, drug fora such as Bluelight, UK Chemical Research, Drugs-Forum, 
Reddit, TripSit and PsychonautWiki. 
 
3. Results and discussion 
3.1. Psychostimulants 
3-Fluorophenmetrazine (3-FPM;(1)), also known as PAL-539, has recently emerged in the 
online market of ‘research chemicals’ and is currently legal to possess and supply in the UK 
as long as it is not for human consumption [4]. This compound is a relatively new 
substanceand there are currently no scientific studies or literature pertaining to it. Psychonaut 
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Wiki and drug fora such as Bluelight refer to the amphetamine-like its properties and3-FPM 
is a close relative to the now no longer used anorectic drug phenmetrazine (2), the chemical 
backbone of which can be likened to amphetamine with the terminal amine in a morpholine 
ring. According to Psychonaut Wiki, 3-FPM has not been used in humans prior to 2014, 
however, psychonaut communities who have experience with the drug have put up rough 
‘guidelines’ for its use. These suggest that a longest duration of action of 5-8 hours occurs 
when taken orally with a dose of 25-50mg orally or 20-35 mg as insufflation for what is 
referred to as a ‘common’ effect [5]. Physical effects described are increased energy levels, 
vasoconstriction, loss of thermoregulation, appetite suppression and an increased heart rate. 
Cognitive effects included increased motivation, focus and euphoria. Nonetheless, the 
stimulant effect was described as being less than that induced by substituted amphetamine 
compounds and users have referred to ‘flu-like’ symptoms with shivers [4,6].Most of its 
effects could be inferred from the effects associated with phenmetrazine and other 
amphetamine-like drugs; therefore, part of this review will include some closely related 
compounds to which 3-FPM is related. 
Phenmetrazine is of the phenylmorpholine class of compounds and was developed as an 
appetite suppressant (anorectic) to be used in conjunction with a low caloric intake diet in the 
short-term treatment of exogenous obesity [7]. It was marketed under the trade name Preludin 
and was allegedly used by the Beatles early during their career to cope with long hours of 
performance. It is an indirect-acting sympathomimetic agent with central stimulant effects, 
and its mode of action and effects are similar to those of dextroamphetamine [7, 8]. Due to its 
high potential for abuse, considered to be more potent than amphetamine, it was withdrawn 
from the market [9]. It has been used recreationally and abused in Sweden in the 1950’s and 
in the USA in the 1960’s and 1970’s before being removed completely from the market [10]. 
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The mechanism of action is highly similar to amphetamine by blocking the noradrenaline and 
dopamine re-uptake transporters in the brain which leads to their prolonged presence and 
hence prolonged stimulation of post-synaptic receptors at the synapse [11, 12]. 
Ritalin or methylphenidate (3) analogues such as 4-Me-TMP (4), made its appearance on the 
NPS market in April 2015 as a methylphenidate (3) replacement for the recently banned 
methylphenidate analogues EPH (5), PPH (6), IPH (7), 3,4-CTMP (8) and HDMP-28 (9) 
[13]. However, 4-Me TMP did not last long among psychonauts as it also was soon put under 
a Temporary Class Drug Order which took effect on the 27
th
 of June 2015 following 
recommendations made by the UK Advisory Council on the Misuse of Drugs (ACMD), 
based on its similarity to methylphenidate in effects and inferred adverse effects [14,15]. 
Currently there are no scientific studies specific to 4Me-TMP as a recreational drug. A search 
on Pubmed using the keywords ‘4Me-TMP’, ‘4-Methylmethylphenidate’ returned no results 
as of 26
th
 of October 2015. Pharmacological data is limited with records of 4Me-TMP as one 
of the analogues of methylphenidate investigated in the treatment of cocaine dependence.  It 
was found to be slightly more potent than methylphenidate at inhibiting the binding of [
3
H]-
WIN35 428, a cocaine analogue used in research on the dopamine transporter [16, 17].  
In psychonaut communities, 4Me-TMP has gained popularity as a psychostimulant during its 
short span of ‘legality’. Users described it as the only ‘research chemical’ with effects closest 
to methylphenidate with a relatively lower potency that is concordant with available scientific 
pharmacological data [18]. Information regarding its effects in the human body can only be 
gleaned from reports of trips as posted or discussed on drug fora. Users reported euphoria, 
decreased appetite and need for sleep, increased alertness and focus and sexual arousal as 
positive and desired effects. Negative effects included increased sweating, tremors and 
tachycardia, however, the degree of the effects was subjective to the user.  Depending on the 
dose administered, 4Me-TMP was reported to be recreational resulting in a clear head and 
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enabling users to improve performance during work or study.  Some users have recognised 
that as a methylphenidate analogue, 4Me-TMP may also have addictive potential, although so 
far, no compulsion to re-dose has been reported [19, 20].   
4Me-TMP has been mainly taken orally or by insufflation and oral doses vary from a 
recommended threshold of 25mg to 90-125mg as a heavy dose, with an onset of action within 
minutes and a duration of action of 4-6 hours. For insufflation, doses are smaller with a 
threshold of 10mg and a heavy dose of over 70 mg with an onset of action within minutes and 
a duration of action of 2-5hours.  Doses are sometimes ‘boosted’ after 3 hours of 
administration for a prolonged effect [18,19,21,22].  Varying degrees of harm from drug-drug 
interactions when using methylphenidate are also warned of on the Tripsit website. For 
instance, concomitant use of stimulants and tramadol are said to increase the risks of seizures 
and are qualified as dangerous. Increased risk of serotonin syndrome is noted with 
simultaneous use with monoamine oxidase inhibitors and 2C-T-x compounds(e.g. 10)while 
combinations with NBOMe, cocaine, dextromethorphan and methoxetamine are recognised 
as causing excessive sympathetic stimulation and posing unnecessary stress on the heart.  
Excessive anxiety with persistent thought-loop is also purported to occur when 4Me-TMP is 
used with psychedelics such as mescaline. 4Me-TMP as a psychostimulant is also said to 
decrease the perception of drunkenness and increase the risk of drinking excessively till the 
passing out point [21]. 
The fora threads on 4Me-TMP are relatively short possibly because of its short span of use as 
an NPS.  Nevertheless, users have so far reported few negative effects and are positive about 
4Me-TMP with people still seeking it out.  New posts appear to come from users who are 
apparently based outside the UK for example in Sydney [18], which suggests that 4Me-TMP 
has spread globally. For the time being, there is still no scientific evidence specific to 4Me-
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TMP (26
th
 October 2015) apart from its inferred effects from structural similarity to 
methylphenidate, to validate its permanent ban under UK law. 
Methiopropamine 
Methiopropamine (11) as an NPS was first reported following a seizure in Finland in January 
2011[23]. Its synthesis however, dates back to the 1940s when it was synthesised by Blicke 
and Burckhalter as an analogue of methamphetamine, where the phenyl ring was substituted 
with a thiophene ring in order to compare effects on blood pressure [24].  
Since its appearance online as a research chemical in late 2010, methiopropamine has become 
an established NPS used recreationally and evading control under the UK legislation until a 
temporary class drug order at the end of 2015. According to an internet snapshot study 
conducted in June 2013 in accordance with EMCDDA methodology, it was found that 
methiopropamine is readily available over the internet with 45% of vendors identified as 
being UK-based.  It is sold mainly in powder form in amounts ranging from 150mg to 4kg 
[25]. This NPS was also detected in pooled urine collected from urinals placed in Central 
London on Friday and Saturday nights in 2012 as part of a pilot study to understand 
prevalence of NPS use [26]. It was also detected in the blood samples from drivers in Norway 
[27]. 
An analysis of the metabolites of methiopropamine from rat and human urine by GC-MS and 
LC-HR-MS was conducted by Welter et al.  This proposed that methiopropamine underwent 
a combination of N-methylation and hydroxylation at the side-chain and thiophene ring 
respectively before glucuronidation and sulfation.  The CYP450 enzymes involved were 
CYP1A2, CYP2C19, CYP2D6 and CYP3A4 [28]. 
It seems that users have been utilizing methiopropamine as a performance enhancer to cope 
with work, study and bereavement as well as recreationally [31, 32, 38]. Methiopropamine is 
being ingested orally, smoked, used as an insufflation, taken rectally or injected intravenously 
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by psychonauts depending on the effects desired.  For instance, small doses of 10mg taken 3 
hourly by IV injection to maintain a high or a bolus of 40-50mg for a ‘rush’ have been 
suggested [32].  The threshold dose is noted as 10mg with a 60mg+ dose as being heavy.  
Onset of action is within 30-60minutes with the effects peaking at 2-4 hours, with a coming 
down that lasts 2-3 hours and an afterglow experienced for 1-3 hours [33]. Insufflation is 
reported to leave a bad taste which may be due to the sulfur atom in the molecule but 
provides the same intense rush as IV injection with a shorter duration of action [32].  An 
analysis of the pyrolysis products of methiopropamine under the same conditions when 
smoked by users found that they were mostly the same as methamphetamine. However, other 
products were also formed such as beta-keto-methiopropamine, whose properties are 
unknown, N-methyl methiopropamine which is psychoactive, 2-methylthiophene which is 
toxic and a bicyclic tetrahydropyridine compound with a structure similar to the anti-platelet 
drug clopidogrel [29]. 
As an analogue of methamphetamine, methiopropamine has also been reported to induce 
similar effects.  This was supported by a study of neurochemical profiling of NPS by Iversen 
et alin which methiopropamine was found to be a potent inhibitor of noradrenalin, dopamine 
and to a lesser extent serotonin re-uptake comparable to amphetamine [30]. Users report an 
increased alertness, energy and focus, sexual arousal and euphoria on drug fora which is 
described as a ‘rush of adrenaline’. Side-effects also noted were high-blood pressure, 
tachycardia, anxiety, sweating and shaking, nausea, dehydration, difficulty urinating and a 
significant loss of appetite and sleep which could last for days. Quite a few users also 
reported chest pain, palpitations and headaches sometimes comparableto a heart-attack. Users 
recommended taking multivitamins, drinking plenty of water and Gingko biloba for its 
vasodilating effects to minimise the harmful effects of methiopropamine. Negative effects 
were said to increase with repeated dosing and to cause hallucinations at high dose. Chronic 
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use multiple times a day and/or over several consecutive days was reported to cause 
psychosis, hallucinations and heightened fear and anxiety, depression and aggressive 
behaviour on withdrawal [31–39]. Methiopropamine was also regarded as highly addictive 
with a strong compulsion to re-dose and binge accompanied by a loss of inhibition at high 
doses. This addictive character was suggested to be in part a psychological need to feel the 
‘intense euphoric rush’ by users [35, 32]. Tolerance was also said to build up very quickly 
with loss of positive or desired effects [38, 39]. In drug fora, prospective users are warned not 
to binge on methiopropamine and an awareness of its potentially-life threatening side-effects 
seems to be prevalent [31-39]. 
Methiopropamine use has already claimed lives as it continues to gain followers despite some 
discouraging user reviews online [32, 39].  In 2012, two methiopropamine-related deaths 
were first reported in the UK [23] while the first ever case in Australia was reported in 2015 
where a post-mortem investigation found 38mg/L of methiopropamine in the blood of the 
deceased [40]. Acute toxicity related to methiopropamine where 400ng/ml was found in 
urine, has also been reported.  In that particular case, however, the user bought their samples 
from a Central London market stall under the name of ‘Quicksilver’. Considering that the 
only reference to ‘Quicksilver’ in a recreational drug context that could be found online was 
of methoxetamine, it is possible that the victim may not have been aware of what they were 
ingesting [41].   
Methiopropamine is appealing to many users as a euphoric psychostimulant that can be 
employed in multiple situations in spite of its notorious side-effects. Use will probably 
continue to spread worldwide via its boundary-less cyber foothold unless any action is taken 
whether in terms of legislative control or harm reduction and drug use education measures. 
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II. LEFETAMINE-DERIVED DISSOCIATIVE ANAESTHETICS 
Following the UK ban in February 2013 on all arylcyclohexylamines in an attempt to curtail 
the spread of PCP and ketamineanalogues, a new class of dissociative anaesthetics known as 
diarylethylamines based on lefetamine (12)among which can be found ephenidine(13), 
diphenidine (14) and methoxyphenidine (15), hit the NPS market as crystals, powder and 
pellets to circumvent the law [42].  Diarylethylamines, which are far from being novel, have 
actually been synthesised and documented as far back as 1924 [43]. Diarylethylamines are in 
fact, analogues of the now withdrawn and controlled drug lefetamine (12), which was 
introduced as an opioid analgesic in the 1940s and marketed as Santenol [44]. 
However, despite their structural resemblance to lefetamine, these diarylethylamines do not 
have the same pharmacological activity, mimicking instead the effects of PCP and ketamine, 
and their respective analogues function by uncompetitive NMDA-receptor antagonism and 
are being marketed as their legal replacement by online chemical vendors [43, 45]. Indeed, 
from a thread on bluelight, it seems that lefetamine and lefetamine-derivatives have been 
compared to the arylcyclohexylamines PCP and ketamine and their use as possible 
recreational drugs was discussed as early as 2006 [46].  
While these compounds have been gaining in popularity across the psychonaut communities, 
again little is known about them. Most of the information reported about their physiological 
effects in humans comes from online drug fora and some from cases of NPS poisoning sent to 
emergency services.  So far, Sweden has already classified them as hazardous to human 
health [47] and this review seeks to bring an overview of the information available so far. 
Ephenidine (13), (N-ethyl-1, 2-diphenylethylamine (NEDPA)) 
Ephenidine first appeared on the NPS scene in 2008 when it was seized alongside 
NPDPA(16), another lefetamine derivative, by the German police. Nonetheless its 
amphetamine-like stimulant properties had already been described in the 1940s [48]. From 
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the metabolites collected from rat urine, it was inferred that ephenidine was completely 
metabolised and most likely underwent a combination of N-alkylation, mono- and bis-
hydroxylation of the benzyl ring followed by methylation of one of the two hydroxyl group 
metabolites at phase 1, and hydroxylation of the phenyl ring after N-dealkylation, 
glucuronidation and sulfation of all hydroxylated metabolites in phase 2 [48] Since the 
metabolism of ephenidine has been found to involve at least four CYP-450 enzymes to 
varying degrees, it has been purported that ephenidine may not give rise to significant drug-
drug or drug-food interactions [44]. 
In the Psychonaut communities, a thread was first dedicated to ephenidine and other related 
dissociative NPSin late December 2014 on Bluelight.  However, it seems that ephenidine is 
only recently starting to gain wider acceptance and popularity according to the drug fora 
studied [49, 50].  Often, reference is made to its smooth or ‘silk-like’ come-up compared to 
other dissociative anaesthetics [52] but also of a tendency to feel dehydrated.  The experience 
is also viewed as much more positive with a greater cornucopia of visual stimulation and 
hallucinations and also as less ‘out-of-body’ at regular doses. In some cases, users reported its 
effects as more ‘spiritual’ or ‘magical’ with an enhanced appreciation for music and colours 
[51, 52, 50]. One user even stated that ephenidine surpasses ketamine, PCP and all other 
dissociatives [53]. Ephenidine has also been reported to have mild psychedelic effects while 
scarcely affecting ‘functioning as a person’ [56].  Furthermore, it was also seen as an 
alternative to ketamine and methoxetamine by another user [57].   
Psychonauts have been administering the drug orally, rectally, by sniffing or vaping and by 
the IV route.  Doses employed are sometimes seen to be quite high, ranging from 150mg to 
600 mg in some cases to achieve desired effects, though websites such as Psychonaut Wiki 
indicates a threshold of 60mg with a 200 mg+ dose being seen as ‘heavy’ [50, 54]. This 
suggests that ephenidine might be less potent or that the negative effects are more tolerable. 
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Ephenidine is also reported to have a slow onset depending on individuals ranging from 10-
30minutes to 1.5-3 hours but also a longer duration of action of 5-7hours [50, 54, 55].  Full 
recovery from the dissociative effects also seem to vary among individuals with some still 
feeling wobbly after 15hours after a 250 mg dose while others took a full 24 hours to recover 
after a 200 mg dose [55]. This may of course be as a result of the quality of the product as 
well as individual pharmacogenomic responses. 
Overall, most ‘user reviews’ appear in favour of ephenidine with apparently no distressing 
mental stimulation and a more enjoyable trip with seemingly no negative effects except for 
residual dissociative effects post use.  Nonetheless, ephenidine is regarded as having a 
potential for addiction and prospective users are warned to use it carefully [57].   
On the side, two other variants of ephenidine that so far seem to be less popular among 
psychonaut communities are 2-chloro-ephenidine(26) and 2-MeO-ephenidine(27) [49]. 
Diphenidine (14)(1-(1,2-Diphenylethyl)piperidine) 
Diphenidine (14) was first synthesised in 1924 by Christiaen who used a modified Brulyants 
reaction which would later be used by Maddox to synthesise PCP [43].  Though it was 
launched earlier than methoxyphenidine, it is less popular [58]. 
As a diarylethylamine, diphenidine has been investigated for neuroprotective effects on 
neurones in the hippocampus as described in a 1989 patent and furthermore its ability to 
suppress cough as an antitussive agent in dogs has also been studied. These past observed 
properties are what might have made it a candidate as a research chemical [59]. The NMDA-
receptor antagonist effect has recently been confirmed in-vivo using rat hippocampal slices 
and was found to be similar to ketamine in reducing NMDA-mediated field excitatory post-
synaptic potentials at 30M [59]. Though not of the same chemical class, diphenidine 
definitely does act as a pharmacological analogue to the dissociative drug ketamine.  
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Dopamine and serotonin re-uptake inhibition and mu-opioid receptor affinity are purported 
by vendors but have however, not been studied [60]. 
According to Tripsit, a normal dose of diphenidine would be approximately85-110mg, with 
an onset of action of 10-30 minutes, a duration of 2-5 hours and an ‘after-glow’ effect of up 
to 4-24hours [61]. The most common route of administration is oral or sublingual. Blocked 
nose or inflamed sinuses have been reported with insufflation, although it is believed to have 
a quicker onset of action by this route requiring a fifth of the oral dose [63, 61]. 
Diphenidine is described as mildly stimulating and mostly amnesia-inducing, crippling the 
recall ability of the user which may potentially cause loss of control over one’s own 
behaviour [62]. An example is that of a previous ketamine user who overdosed on 
diphenidine orally at 310mg, was violent with the paramedics who came to take him to 
hospital and could not remember any of what had happened [63]. Other effects noted are 
those of sensory dissociation, loss of inhibition, and significant visual and internal 
hallucinations. Several users also reported high blood pressure and tachycardia. This was 
reflected in non-fatal intoxication cases of diphenidine observed in Sweden [61, 45].  
Diphenidine has not been very popular with many users reporting negative and sometimes 
both physiologically and psychologically troubling experience described by one user as being 
‘sucked down into a shrieking vortex of insanity’ [58]. Of most concern is the steep dose 
response curve reported with a rapid build-up of tolerance at higher doses and high addiction 
potential, which is described as very compulsive [63, 45, 64].  Diphenidine has even been 
described as ‘evil’ by another user [64]. 
Methoxyphenidine (15), 1-[1-(2-methoxyphenyl)-2-phenylethyl] piperidine 
Methoxyphenidine is also member of the diarylethylamine group that has been screened for 
the potential treatment of neurotoxic injury according to a 1989 patent [66]. 
Methoxyphenidine appeared shortly after diphenidine and gained a rapid rise in popularity 
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relative to the latter despite an initial dearth of reports of previous human use of the 
compound [58].  Methoxyphenidine has been and is still being used extensively by the 
psychonaut communities.  
However, while it is being marketed by online vendors as a replacement for methoxetamine 
and ketamine, the effects of methoxyphenidine are reported to be qualitatively closer to those 
of dextromethorphan, an antitussive which has been abused. Subjective physical effects 
which include tactile disconnection, a spontaneous tactile sensation described as ‘body high’ 
and loss of motor control are reported to increase with increasing dosage and are reported to 
feel like those induced by dextromethorphan [67].   
Furthermore, the cognitive effects are seen as different from all other dissociatives with the 
user still being in control and less confused even at higher dosages to bring about the same 
subjective intensity when using methoxetamine, dextromethorphan or ketamine [58, 67]. A 
methoxyphenidine experience has been qualified as ‘introspective’ by one user-blogger [70].  
An in-depth review of harm reduction and online consumerism of methoxyphenidine among 
psychonauts conducted by Van Hout and Hearne supported that its effects are perceived as 
unique and result in a more ‘clear-headed’ sensation. It was also viewed as much better than 
diphenidine in that it is less ‘havoc-provoking’ with more enjoyable effects [58].  
Routes of administration are oral, sublingual, rectal, insufflation and by IV [58].  
Insufflations are said to irritate the nasal mucosa significantly [68, 70] and a numbness of the 
tongue is said to occur with IV administration and is therefore not the most favoured route 
[58].  Psychoactive effects are said to start at a dose ranging from 30 to 50mg with 150+ mg 
being regarded as giving strong effects. The onset starts from 30 to 60 minutes with a 
duration of action of between 6-8hours and after-effects are described as ‘after-glow’ of 1-
3hours [67, 69].  Sometimes, even at higher doses of 200mg, some users reported being 
reasonably lucid [56]. Whilst a steep-dose response curve has been reported, it is also said 
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that re-dosing is unnecessary as there is not much enhancement of positive effects but instead 
a higher risk of experiencing negative side-effects such as amnesia [43, 68].  Nevertheless, 
the dose-response effect of methoxyphenidine is reported as inconsistent and unpredictable 
with different users experiencing a differing degree of intoxication/side-effects at the same 
dosage [68].  Novice users as well as users who are experienced with dissociatives are often 
advised to start at the lowest dose as even with past dissociative usage, the effects of 
methoxyphenidine have been reportedly experienced as strong [70, 71]. 
On drug fora, users are reminded not to ‘push too far’ with this compound as it has been 
reported to cause chest pains, palpitations, tachycardia, high blood pressure and sometimes 
seizures requiring hospitalization [43, 56, 58, 70]. Indeed, during a relatively short span of 
use, cases of methoxyphenidine-related deaths and acute toxicity have already been reported 
[45, 65, 66].  An acute toxicity case of a 53 year old Caucasian male presented with 
hypertension at 220/125mmHg and tachycardia of 112bpm was treated with lorazepam, 
whilst an enlarged heart was found at the autopsy of two of the fatal cases attributed to 
methoxyphenidine [65, 66].  The acute toxicity case also developed opisthotonus and 
horizontal nystagmus upon losing consciousness before reaching a Glasgow Coma Scale of 
10 [65]. 
Despite the grave side-effects of methoxyphenidine that are possible, its positive effects of 
mood-elevation and as a brain stimulant with ‘responsible’ use were seen as important 
enough to lead psychonauts to speculate about its medicinal potential as an antidepressant 
and in psychotherapy [58].   
Possible further lefetamine-based dissociative anaesthetics may find their roots in previously 
studied analogues of lefetamine as suggested by one Bluelight thread dating back to 2008 
which briefly discusses DMPP (19), a compound investigated for analgesic properties [72].  
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On the whole, the psychoactive agents, ephenidine, diphenidine and methoxyphenidine are an 
emerging class of dissociative anaesthetics that have not been explored in that sense before. 
Their effects are being widely reported by psychonaut communities, definitely warrants 
further investigation and it is reasonable to expect new lefetamine analogues on the NPS 
market in the future. 
III. PHENYLAKYLAMINE HALLUCINOGENS 
bk-2C-B 
 
Alexander Shulgin was the first to synthesise the phenylalkylamine hallucinogens 2C-B (20), 
DOB and DOM and described their syntheses and effects in PiHKAL [73].  While DOM and 
DOB were already established, 2C-B really flourished in the recreational drug use sphere in 
the mid-1980s as the best alternative to LSD and psilocybin [74, 75].  However, the 2C-B 
class were soon banned in the US in 1985 and placed in Schedule 2, as Class B drugs in the 
UK. However, 2C-B still found its way into raves being often disguised as MDMA. 
In recent years, as an attempt to find a legal substitute to 2C-B, vendors have come up with 
bk-2C-B(21)also known as beta-keto 2C-B, which hit the shelves of online head-shops in 
mid-2013 being sold as powder or crystals.  Because of its structure, bk-2C-B is not regulated 
to date in the UK or Ireland though it can be considered as the beta-keto analogue or a 
cathinone analogue of 2C-B [76].  bk-2C-Bappeared online in 2007 in a Bluelight forum 
thread discussing its potential as a future ‘legal-high’ replacement for 2C-B focusing on its 
possible dimerisation (22) which could lead to inactivity of the compound in-vivo[77].  An 
even earlier appearance can be traced back to 2004 in a paper published by Glennon et al as 
an intermediate in the synthesis of beta-oxygenated analogues of a 5-HT2A serotonin receptor 
agonist investigated in the treatment of intraocular pressure [78].   
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Analogous to 2C-B, bk-2C-B is deemed to be active at serotonergic receptors although 
scientific pharmacological data are limited.  It was gathered from anecdotal evidence posted 
on drug fora that bk-2C-B provides a psychedelic experience comparable to 2C-B [77], 
curiously though no article on bk-2C-B is yet available on Psychonaut Wiki. From other 
sources, users describe typical psychedelic effects of visual hallucinations, sensory 
enhancement and sometimes a greater appreciation of food and music is mentioned with 
euphoria and empathogenic experiences. [77,79,80]. Predominantly bk-2C-B is viewed as 
having scarce negative effects and seems to be appreciated though it is not always a favourite 
regarded by a few as ‘bland’ or ‘empty’ with little excitement and some users said they still 
prefer 2C-B. The quality of the trip is said to be dependent on the state of mind prior to taking 
the drug [77, 82, 81].  
It is also said to be 10 times less potent than 2C-B, initially requiring higher doses for the 
same effect but past a 150mg dose, a steep dose-response curve is reached which warrants 
careful proceeding. The drug has a threshold of 50-60mg and a 150mg+ dose is seen as heavy 
while many users report that a proper ‘trip’ is achieved at 100mg.  The drug has been taken 
orally, rectally and n insufflated with encapsulation of an oral dose preferred over dissolution 
in water to avoid the aforementioned dimerisation. Reports indicate that it has an onset of 
action of 20-70 minutes and a duration of 8-12 hours [77, 79, 82]. However, the effects of bk-
2C-B have also been reported as inconsistent, one report even describing it as ‘Russian 
Roulette’ as the onset and duration of action were not always predictable at a given dose [83] 
Despite being apparently relatively ‘safe’, there has been a report of a 25 year-old male user 
with no previous history of heart disease who experienced a cardiac arrest following a dose of 
140mg of bk-2C-B.The person suffered amnesia lasting two days after re-gaining 
consciousness and suffering from severe rhabdomyolysis [84].  Indeed, from several posts, 
psychonauts state that they are not willing or that it is not necessary to try a dose above 100-
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120mg as they deemed that the desired effects do not increase significantly and that it might 
be more dangerous to do so [77,82]. 
It is to be noted that despite being on the market since mid-2013 and showing similarity of 
action to 2C-B from drug forum posts, bk-2C-B has not conquered the recreational field of 
psychonauts in spite of being qualified as a ‘good chemical’.  
IV. PSYCHEDELICS – LSZ AND 1P-LSD 
NPS analogues of the classic psychedelic LSD (23) include two potent analogues LSZ 
(24)and 1P-LSD(25).  Very little scientific data exists regarding their pharmacological 
properties while they have been widely adopted by the psychonaut community ever since 
their appearance on the NPS market. 
LSZ; (24) (8β)-8-{[(2S,4S)-2,4-Dimethylazetidin-1-yl]carbonyl}-6-methyl-9,10-
didehydroergoline 
LSZ is currently classified as a Class A Schedule 1 Drug in the UK since 6
th
 January 2015 on 
recommendation of the ACMD based on the fact that LSZ is an analogue of the controlled 
drug LSD and as a tryptamine-based drug it will have similar effects [85].  LSZ was 
synthesised and documented back in the early 2000’s by Nichols et al as a conformationally 
constrained analogue of LSD. It was found that the S, S isomer of LSZ was slightly more 
potent than LSD itself and showed greater binding affinity to 5-HTA receptors in rats, 
therefore being responsible for its hallucinogenic properties [86]. It appeared on the NPS 
highs market 7 years later in 2009 [87]. 
1P-LSD; (25) (6aR,9R)-4-propionyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-
fg]quinoline-9-carboxamide 
1P-LSD is only a recent addition to the lysergamide family, appearing in January 2015 and 
has apparently been designed to provide an alternative to LSZ as it was banned. 1P-LSD is 
also believed to be slightly more potent than its parent drug LSD [88]. This was demonstrated 
18 
 
in a study in mice by Brandt et al where it was found to display approximately 38% more 
potency than LSD [89].   
Both LSZ and 1P-LSD have been marketed in the form of blotters containing usually 150 
micrograms of the substance which is placed under the tongue  in a similar fashion to LSD.  
1P-LSD is also available in tablet or ampoule forms [98].  Threshold dosage for LSZ is said 
to be 80micrograms and between 150-300micrograms to achieve a common effect.  The onset 
of action is 90-120minutes with a duration of action lasting from 7 to 10 hours.  After-effects 
can be felt for up to 1 to 3 hours [90].  On the other hand, 1P-LSD seems to be more potent 
with a threshold dose of 50 micrograms and 150+ micrograms as a heavy dosing.  The onset 
of action is also faster, starting at around half the time and a much longer duration of action 
lasting up to 12 hours with after-effects lasting up to 24hours [88]. 
Users report mostly similar effects to those of LSD with experiences such internal-external 
visual hallucinations, loss of ego, empathy, euphoria, increased tactile sensation and 
perception alteration.  Tripping experiences are subjective and varied with the occurrence of a 
positive experience more likely with a ‘positive mindset’ and a negative experience more 
likely with the opposite or with exposure to an object of fear and/or disdain during tripping.  
Users also sometimes reported ‘self-realisation’ or ‘spiritual’ experiences whilst tripping.  
The effects have been reported to significantly alter cognitive functions enough to endanger 
the user if in a potentially unsafe situation in that state such as walking on roads.  Physical 
manifestations are sweating, chills, pupil dilation, nausea and decreased appetite. Overall, 
however, most trip reports of LSZ or 1P-LSD are positive with users often reporting a more 
positive outlook on life afterwards and an agreeable experience they are willing to repeat.  So 
far, no acute toxicity cases or hospitalisation were reported with either LSZ or 1P-LSD.  Both 
LSZ and 1P-LSD are deemed to have no addictive potential and very low toxicity by users 
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[88,90-101].  One user, however, did report excessive nausea after taking a significant dose 
of 600micrograms of LSZ but acknowledged to having overdosed [95].  
It seems that to date, lysergamides remain popular amongst psychonauts with uses ranging 
from recreational to introspective to spiritual.  Furthermore, their ‘apparent safety’ and low 
addiction and recoverable tolerance make them a drug of choice of this community.  
V. BENZODIAZEPINES– FLUBROMAZEPAM 
Benzodiazepines are used in the psychonaut community to temper the effects of stimulants 
and hallucinogenic drugs to ‘come down’ while some people may use them as self-
medication for anxiety disorders when they cannot get a prescription.  Benzodiazepines are 
also used in the clinical setting to treat cases of acute toxicity related to NPS use [102].  
However, benzodiazepines are also used recreationally and the scheduling of the etizolam 
and phenazepam in 2012 led to the advent of new designer benzodiazepines made available 
to the public through online vendors.  Flubromazepam (26) is the second of the class to be put 
on the market and was a drug candidate described first in 1962 by Sternbach et al.  Its 
potency is said to be possibly higher than those of bromazepam, diazepam and nitrazepam 
[102,103].   
Research into the pharmacokinetics and pharmacodynamics of flubromazepam is pretty 
scarce with only one study found on Pubmed at the time this review where one of the authors 
actually ingested 4mg of the drug to obtain data.  Flubromazepam has been reported as 
having a half-life of more than 106 hours with metabolites detectable by LC-MS/MS for up 
to 28 days after consumption.  However, detection of the drug with immunochemical assays 
were difficult and may indicate the potential use of flubromazepam in drug-facilitated crimes 
or in situations where drug-testing is performed [103]. 
The effects reported in psychonaut drug fora are typical of benzodiazepines such as muscle 
relaxant, anxiolytic, hypnotic and sedation and amnesia noted at higher doses.  For some 
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users, flubromazepam is regarded as more anxiolytic than hypnotic and for others the reverse 
was true.  The routes of administration employed seem to be mainly oral, sublingual and 
rectal as the drug comes mainly as pellets of 4mg or 8mg. Flubromazepam indeed seems to 
be quite potent with a threshold dose of 3-5mg and a heavy dose of 16+ mg.  However, the 
onset of action is not immediate, taking between 30minutes and even up to 6 hours before 
any effect is noted.  This has led many to overdose on their first attempt with unpleasant 
consequences.  The effects are also reported to last for up to a few days.  Users seem to 
recognise that this long duration of action can have potential impact on safety when driving 
or operating machinery.  The danger of cumulative toxicity with reported dosage is also 
mentioned as is its addictive potential [104-108].  One user even reported withdrawal 
symptoms as soon as after one week’s use [109]. Concomitant use with other depressants 
such as alcohol or GBH is warned against to avoid potential respiratory depression [104]. 
Nonetheless, flubromazepam is regarded as one of the ‘best’ NPS benzodiazepines with the 
effects viewed as pleasant with a few cases of appreciated mild psychedelic effects reported.  
Due to its apparent greater perceived effects than diazepam, some users have discussed its 
use in treating alcohol withdrawal instead of the latter [106]. Furthermore, awareness of the 
difficulty to detect in immunochemical assays is already causing some benzodiazepine users 
to consider it to escape drug-testing [110].  
Whether or not flubromazepam’s potential as a useful drug candidate can be revived is yet to 
be determined with the lack of research on this substance.  Meanwhile flubromazepam 
continues to remain in the confines of the grey area of legislative control along with other and 
emerging designer benzodiazepines without any reliability of safety of use.   
4. CONCLUSION 
From this review, the dire lack of pharmacological data available on these substances was 
obvious as was their popularity of use among psychonauts.  A trend observed in most of the 
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compounds selected was their origin from old patents and papers on drug candidates which 
have not been developed further and which can be found online.  Not only was the wealth of 
scientific information exploited by research chemical vendors themselves, but also actively 
discussed by psychonauts on drug fora even before the appearance of these NPS on the legal 
high market as is the case of bk-2C-B or lefetamine-based drugs.  As such, it makes sense to 
consider the content on drug fora as well as previous or abandoned drug candidates to try and 
spot upcoming NPS.  Furthermore, it should be noted that trip reporting on drug fora provides 
a wealth of information on the effects of NPS on the human body albeit by subjective views, 
and may also be a trend-setter in the development of future NPS.  Another interesting issue 
was that NPS were discussed not only as recreational drugs but for their therapeutic value in 
treating conditions such as depression and anxiety, for instance, in the case of ephenidine.  Of 
concern, is the very strong addiction potential of some drugs reviewed such as diphenidine or 
the potentially hazardous and easily overdosed psychostimulants and psychedelics and the 
ease of access to them. It should be noted that acute toxicity cases requiring hospitalization 
and even deaths ensuing from NPS use have also been well reported.    
In any case, NPS which represent a largely unknown and rapidly expanding territory in an era 
of globalization and instantaneous access to information through the World Wide Web, will 
not be easy to conquer nor overlook. It may not be completely surprising if the next 
generation of antidepressants, psychotherapy counselling aid or the next schizophrenia-
modelling drugs were to come from NPS nor would it be surprising if the next addictive or 
crime-facilitating drug were to come from the NPS as well. 
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